Gensense ist Tod es lebe Tesetaxel!

haltet ihr Genta für ein sicheres Investment? Kann man hier seine Rentenvorsorge aufbauen? Kann es womöglich auch sein dass wir noch mal das all time high testen?  

ich finde es konzentriert sich vieles von allem im Chart und seiner Technik... :-)

so... Zeit für 1 Bierchen :-)  

Nein, er, sie, es trinkt morgens Urin :-)

 

Okay...warte, ich mache grade mal eins auf, hab seit 30 min Feierabend!  Klack...warte...Prost :-) So, gez Füße hoch und abwarten :-)

 

braucht in Deutschland keiner mehr weil alle bald bis 70 arbeiten sollen und die Jahre nach 70 kann man schon überleben.  

Prooooooooost :-) ahh... tut gut, bei der Schwüle...  

JA, das kann einiges! Was trinkst du? Warsteiner, Krombacher, Köpi...?

Ist ja sonst nichts los hier, also lass uns über Biersorten sinnieren :-)

 

unter 0,24 cent pro halber Liter,es sei denn Sonderangebot.Morgen auch bei Genta .  

Veltins ist meine Hausmarke...

ich bin aber kein Schalker^^ neulich wurde ich im Bus bedroht, weil ich auf dem Weg inne Stadt eine Flasche "Schalker Pils" trank..., ich hab gesagt, du kannst mich mal ganz gepflegt am..., im... und um..., dann gings aber los^^

Warsteiner & Krombacher sind beide auch sehr bekömmlich :-)  

und du?  

Grade Warsteiner :-) Bin auch kein Schalker, um ehrlich zu sein, schaue ich Fussball nur, wenn unsere Nationalmannschaft spielt. So, jetzt mach ich mir noch lecker eins auf und dann geht es in die Falle so langsam. So, dir und dem Rest der Geimende alles Gute und bis morgen. Gut's Nächtle ins Ländle :-)

 

ausgezeichnet... das mundet...

auch dir gute N8!  

Irrgendwie habe ich das Gefühl, dass es heute oder morgen nicht knallen wird.

Mein Gefühl hat mich schon immer getäuscht und deshalb lege ich mir wieder eine Posi ins Depot.

 

keine Kauf ud Verkaufsempfehlung !

 

Handelsplatz: Stuttgart
0,15 €  <----------

+0,136 €

+971,43 % <--------------

11:58:33

http://www.wallstreet-online.de/aktien/genta-aktie 

 

 

Das sind wie immer elektronische Störungen nach einem Gewittersturm. Bei meiner Anzeige sehe ich nichts. Ist wohl nur eine optische Täuschung. Oder schlimme Vorboten für einen R/S. Ich warte ab. Vorsicht, vorsicht, Ray legt sich schon auf die Lauer.  

Heute hat mir ein Spatz vom Dach zugezwitschert, dass etwas ganz Großes im Busch ist.

Ich weiß nur nicht wie ich das deuten soll 

 

 

 

...als der Blitz einschlug, da hat er viel sinnloses Zeugs gezwitschert. Danach sass er rum wie eine gebratene Taube. Gerupft und....  

http://www.world-of-stocks.com/rt_data/getad  

   

 

 

                                                                                               

 

 

http://finance.yahoo.com/news/...From-pz-3161127310.html?x=0&.v=1

Tesetaxel Results From Multiple Dose-Ranging Clinical Trials Updated at ASCO

tweet
Email
Print
Press Release Source: Genta Incorporated On Wednesday June 8, 2011, 8:40 am
-- Safety of weekly dosing schedule provides "dose-dense" option
-- Low incidence of neuropathy despite extended therapy
-- Published and ongoing combination trials with capecitabine (Xeloda(R))

BERKELEY HEIGHTS, N.J., June 8, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA - News) announced updated results from multiple dose-ranging trials of tesetaxel, the leading oral taxane in clinical development. Together, the trials show a consistent and predictable safety profile along with clinical activity used alone or combination with capecitabine (Xeloda(R); Hoffman LaRoche, Inc.), the leading oral fluoropyrimidine used in patients with breast cancer and gastric cancer. Updated results, published in conjunction with the 2011 annual meeting of the American Society of Clinical Oncology (ASCO), are summarized as follows:

Three Phase 1 studies of tesetaxel administered as a single agent have been completed. Together, these trials show that 27 mg/m2 is a safe starting dose, and that subsequent doses can be escalated to 35 mg/m2 depending upon individual patient tolerance. The principal adverse reaction has been neutropenia. Hypersensitivity reactions have not been observed.
Two studies (one completed, one ongoing) have examined the safety, dosing and pharmacokinetics of tesetaxel administered in combination with capecitabine. The completed study, which showed no adverse drug interactions or difference in pharmacokinetics when the drugs were co-administered, was recently published. An abstract of this new report is available here: http://www.ncbi.nlm.nih.gov/pubmed/21547572.
Ongoing dose-ranging studies include:

A trial of tesetaxel plus capecitabine administered at the maximally tolerated dose of both agents. The use of this combination is envisioned for future clinical trials, and completion of accrual is expected in June 2011.
A study of tesetaxel in combination with cisplatin and capecitabine as initial therapy for patients with gastric cancer.
A dose-ranging study of tesetaxel (24 to 31 mg/m2 every 3 weeks) in Japanese subjects.
A study of tesetaxel administered weekly for 3 consecutive weeks -- currently open to accrual at a total dose of 45 mg/m2.
"In aggregate, this broad program confirms the tolerable safety profile established using tesetaxel alone or in combination," said Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer. "We continue to expand the profile of tesetaxel use in combination with drugs that comprise the standard-of-care in gastric cancer and breast cancer, our priority indications. Early clinical data suggest confirmation of preclinical data that tesetaxel can overcome standard mechanisms of clinically acquired taxane resistance. The lack of hypersensitivity and significant nerve damage -- coupled with flexible dosing, elimination of premedication requirements, and high levels of patient convenience -- offer important advantages that we are exploring in ongoing trials."

About Tesetaxel

Unlike standard taxanes that must be administered intravenously, tesetaxel is a capsule that is taken by mouth. Compared with the standard agents, clinical and preclinical data show that tesetaxel:

Is active in diseases that are resistant to standard taxanes
Is not associated with serious (occasionally fatal) hypersensitivity reactions
Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
Reduces damage to peripheral nerves
Offers flexible and convenient dosing for patients
Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. A second portfolio compound, Genasense(R) (oblimersen sodium) Injection, is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. The Company has recently announced that a randomized trial of Genasense did not increase overall survival in patients with advanced melanoma. Genta is exclusively marketing Ganite(R) (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite(R) that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company's products or product candidates;
the timing of commencement and completion of any clinical trials;
the Company's assessment of its clinical trials;
the Company's ability to develop, manufacture, license, or sell its products or product candidates;
the Company's ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the risk of bankruptcy;
the adequacy of the Company's patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2011 and its most recent quarterly report on Form 10-Q.



Contact:

Genta Investor Relations
info@genta.com
Media Contact
908-286-3980  

Ray hat heute ein interessantes Update zu Tesetaxel und vorläufigen Berichten zur ASCO vorgestellt:

Bericht ist hier zu finden:
http://finance.yahoo.com/news/...From-pz-3161127310.html?x=0&.v=1

und die nun veröffentlichten Ergebnisse sind vorab in einer Fachzeitschrift erschienen.
Abstract dazu hier:
http://www.ncbi.nlm.nih.gov/pubmed/21547572  

news : http://www.globenewswire.com/newsroom/news.html?d=223967

 

gleich ist us börsen eröffnung